{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:11:32Z","timestamp":1775193092045,"version":"3.50.1"},"reference-count":59,"publisher":"Becaris Publishing Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Indirect treatment comparisons (ITCs) are anchored on a placebo comparator, and the placebo response may vary according to drug administration route. Migraine preventive treatment studies were used to evaluate ITCs and determine whether mode of administration influences placebo response and the overall study findings.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            Change from baseline in monthly migraine days produced by monoclonal antibody treatments (subcutaneous, intravenous) was compared using fixed-effects Bayesian network meta-analysis (NMA), network meta-regression (NMR), and unanchored simulated treatment comparison (STC).\n            <jats:bold>Results:<\/jats:bold>\n            NMA and NMR provide mixed, rarely differentiated results between treatments, whereas unanchored STC strongly favors eptinezumab over other preventive treatments.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Further investigations are needed to determine which ITC best reflects the impact of mode of administration on placebo.\n          <\/jats:p>","DOI":"10.57264\/cer-2023-0021","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T13:57:33Z","timestamp":1684936653000},"source":"Crossref","is-referenced-by-count":5,"title":["Comparison of indirect treatment methods in migraine prevention to address differences in mode of administration"],"prefix":"10.57264","volume":"12","author":[{"given":"Christopher G","family":"Fawsitt","sequence":"first","affiliation":[{"name":"Clifton Insight, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Thom","sequence":"additional","affiliation":[{"name":"Clifton Insight, Bristol, United Kingdom"},{"name":"University of Bristol, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane A","family":"Regnier","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin Ying","family":"Lee","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kymes","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene","family":"Vase","sequence":"additional","affiliation":[{"name":"Department of Psychology &amp; Behavioural Sciences, Aarhus University, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_6_2_2","volume-title":"The New Definition of Health Technology Assessment: a Milestone in International Collaboration.","author":"O'Rourke B","year":"2020","unstructured":"O'Rourke B, Oortwijn W, Schuller T. The New Definition of Health Technology Assessment: a Milestone in International Collaboration. Cambridge University Press, Cambridge, UK (2020)."},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2017-0092"},{"issue":"38","key":"e_1_3_6_4_2","first-page":"1","article-title":"Bayesian methods in health technology assessment: a review","volume":"4","author":"Spiegelhalter DJ","year":"2000","unstructured":"Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Bayesian methods in health technology assessment: a review. Health Technol. Assess (Rockv) 4(38), 1\u2013130 (2000).","journal-title":"Health Technol. Assess (Rockv)"},{"key":"e_1_3_6_5_2","volume-title":"NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials.","author":"Dias S","year":"2011","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. National Institute for Health and Care Excellence Royston, UK (2011)."},{"issue":"9","key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/j.pain.0000000000000217","article-title":"Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trials","volume":"156","author":"Vase L","year":"2015","unstructured":"Vase L, Vollert J, Finnerup NB Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trials. Pain 156(9), 1795\u20131802 (2015).","journal-title":"Pain"},{"issue":"2","key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/j.bja.2019.01.040","article-title":"Pain, placebo, and test of treatment efficacy: a narrative review","volume":"123","author":"Vase L","year":"2019","unstructured":"Vase L, Wartolowska K. Pain, placebo, and test of treatment efficacy: a narrative review. Br. J. Anaesth. 123(2), e254\u2013e262 (2019).","journal-title":"Br. J. Anaesth."},{"issue":"7538","key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/bmj.38726.603310.55","article-title":"Sham device versus inert pill: randomised controlled trial of two placebo treatments","volume":"332","author":"Kaptchuk TJ","year":"2006","unstructured":"Kaptchuk TJ, Stason WB, Davis RB Sham device versus inert pill: randomised controlled trial of two placebo treatments. Br. Med. J. 332(7538), 391\u2013394 (2006).","journal-title":"Br. Med. J."},{"issue":"5","key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/M15-0623","article-title":"Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials","volume":"163","author":"Bannuru RR","year":"2015","unstructured":"Bannuru RR, McAlindon TE, Sullivan MC, Wong JB, Kent DM, Schmid CH. Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials. Ann. Intern. Med. 163(5), 365\u2013392 (2015).","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00228-005-0088-5","article-title":"A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials","volume":"62","author":"Macedo A","year":"2006","unstructured":"Macedo A, Farr\u00e9 M, Ba\u00f1os JE. A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials. Eur. J. Clin. Pharmacol. 62(3), 161\u2013172 (2006).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s004150050560","article-title":"Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos","volume":"247","author":"de Craen AJ","year":"2000","unstructured":"de Craen AJ, Tijssen JG, de Gans J, Kleijnen J. Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J. Neurol. 247, 183\u2013188 (2000).","journal-title":"J. Neurol."},{"issue":"30","key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1002\/sim.8759","article-title":"Assessing the performance of population adjustment methods for anchored indirect comparisons: a simulation study","volume":"39","author":"Phillippo DM","year":"2020","unstructured":"Phillippo DM, Dias S, Ades AE, Welton NJ. Assessing the performance of population adjustment methods for anchored indirect comparisons: a simulation study. Stat. Med. 39(30), 4885\u20134911 (2020).","journal-title":"Stat. Med."},{"issue":"6","key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies \u2014 successful translation from bench to clinic","volume":"14","author":"Edvinsson L","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies \u2014 successful translation from bench to clinic. Nat. Rev. Neurol. 14(6), 338\u2013350 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"e_1_3_6_14_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/bs.pbr.2020.06.019","article-title":"Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine \u2014 the monoclonal antibodies and gepants","volume":"255","author":"Chiang CC","year":"2020","unstructured":"Chiang CC, Schwedt TJ. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine \u2014 the monoclonal antibodies and gepants. Prog. Brain Res. 255, 143\u2013170 DOI: 10.1016\/bs.pbr.2020.06.019, PMID: 33008505 (2020).","journal-title":"Prog. Brain Res."},{"issue":"67","key":"e_1_3_6_15_2","first-page":"1","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update","volume":"23","author":"Sacco S","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update. J. Headache Pain 23(67), 1\u201319 (2022).","journal-title":"J. Headache Pain"},{"issue":"1","key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17425255.2022.2049236","article-title":"Positioning the new drugs for migraine","volume":"18","author":"Benemei S","year":"2022","unstructured":"Benemei S, Bentivegna E, Martelletti P. Positioning the new drugs for migraine. Expert Opin. Drug Metab. Toxicol. 18(1), 1\u20133 (2022).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pbr.2020.05.017","article-title":"Update in migraine preventive treatment","volume":"255","author":"Lai T-H","year":"2020","unstructured":"Lai T-H, Huang T-C. Update in migraine preventive treatment. Prog. Brain Res. 255, 1\u201327 (2020).","journal-title":"Prog. Brain Res."},{"issue":"3","key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina M","year":"2020","unstructured":"Ashina M, Saper J, Cady R Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3), 241\u2013254 (2020).","journal-title":"Cephalalgia"},{"issue":"13","key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton RB","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13), e1365\u2013e1377 (2020).","journal-title":"Neurology"},{"issue":"19","key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMra1915327","article-title":"Migraine","volume":"383","author":"Ashina M","year":"2020","unstructured":"Ashina M. Migraine. N. Engl. J. Med. 383(19), 1866\u20131876 (2020).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_21_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117505","article-title":"Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): a network meta-analysis of randomized controlled trials","volume":"427","author":"Masoud AT","year":"2021","unstructured":"Masoud AT, Hasan MT, Sayed A Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): a network meta-analysis of randomized controlled trials. J. Neurol. Sci. 427, DOI: 10.1016\/j.jns.2021.117505 (2021).","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3390\/ijerph19031753","article-title":"The safety and efficacy of calcitonin gene-related peptide (CGRP) monoclonal antibodies for the preventive treatment of migraine: a protocol for multiple-treatment systematic review and meta-analysis","volume":"19","author":"Fern\u00e1ndez-Bravo-Rodrigo J","year":"2022","unstructured":"Fern\u00e1ndez-Bravo-Rodrigo J, Pascual-Morena C, Flor-Garc\u00eda A The safety and efficacy of calcitonin gene-related peptide (CGRP) monoclonal antibodies for the preventive treatment of migraine: a protocol for multiple-treatment systematic review and meta-analysis. Int. J. Environ. Res. Public Health 19(3), 1753 (2022).","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"671845","key":"e_1_3_6_23_2","first-page":"1172","article-title":"Calcitonin gene-related peptide monoclonal antibodies versus botulinum neurotoxin a in the preventive treatment of chronic migraine: an adjusted indirect treatment comparison meta-analysis","volume":"12","author":"Chen Y-Y","year":"2021","unstructured":"Chen Y-Y, Ye X-Q, Tang T-C, She T-W, Chen M, Zheng H. Calcitonin gene-related peptide monoclonal antibodies versus botulinum neurotoxin a in the preventive treatment of chronic migraine: an adjusted indirect treatment comparison meta-analysis. Front. Pharmacol. 12(671845), 1172 (2021).","journal-title":"Front. Pharmacol."},{"key":"e_1_3_6_24_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.105900","article-title":"Monoclonal antibodies as a preventive therapy for migraine: a meta-analysis","volume":"195","author":"Alasad YW","year":"2020","unstructured":"Alasad YW, Asha MZ. Monoclonal antibodies as a preventive therapy for migraine: a meta-analysis. Clin. Neurol. Neurosurg. 195, DOI: 10.1016\/j.clineuro.2020.105900 (2020).","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"3","key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/j.pain.0000000000002365","article-title":"Different routes of administration in chronic migraine prevention lead to different placebo responses: a meta-analysis","volume":"163","author":"Swerts DB","year":"2022","unstructured":"Swerts DB, Benedetti F, Peres MFP. Different routes of administration in chronic migraine prevention lead to different placebo responses: a meta-analysis. Pain 163(3), 415\u2013424 (2022).","journal-title":"Pain"},{"key":"e_1_3_6_26_2","volume-title":"5.06 FREMANEZUMAB, Injection 225mg in 1.5mL pre-filled syringe, Ajovy\u00ae.","author":"Australian Government Department of Health and Aged Care","year":"2019","unstructured":"Australian Government Department of Health and Aged Care. 5.06 FREMANEZUMAB, Injection 225mg in 1.5mL pre-filled syringe, Ajovy\u00ae. Teva Pharma Australia Pty Ltd Ryde, Australia (2019)."},{"issue":"6","key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a phase III randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick DW","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL ARISE: a phase III randomized trial of erenumab for episodic migraine. Cephalalgia 38(6), 1026\u20131037 (2018).","journal-title":"Cephalalgia"},{"issue":"9","key":"e_1_3_6_28_2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer VL","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 75(9), 1080\u20131088 (2018).","journal-title":"JAMA Neurol."},{"issue":"8","key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase III randomized controlled clinical trial","volume":"38","author":"Skljarevski V","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase III randomized controlled clinical trial. Cephalalgia 38(8), 1442\u20131454 (2018).","journal-title":"Cephalalgia"},{"issue":"19","key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"Dodick DW","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19), 1999\u20132008 (2018).","journal-title":"JAMA"},{"issue":"22","key":"e_1_3_6_31_2","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby PJ","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y A controlled trial of erenumab for episodic migraine. N. Engl. J. Med. 377(22), 2123\u20132132 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"e_1_3_6_32_2","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein SD","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME Fremanezumab for the preventive treatment of chronic migraine. N. Engl. J. Med. 377(22), 2113\u20132122 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"e_1_3_6_33_2","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke HC","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24), e2211\u2013e2221 (2018).","journal-title":"Neurology"},{"issue":"6","key":"e_1_3_6_34_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase II trial","volume":"16","author":"Tepper S","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase II trial. Lancet Neurol. 16(6), 425\u2013434 (2017).","journal-title":"Lancet Neurol."},{"key":"e_1_3_6_35_2","volume-title":"Clinical Systematic Literature Review in Migraine Prevention.","author":"Costello Medical","year":"2021","unstructured":"Costello Medical. Clinical Systematic Literature Review in Migraine Prevention. Cambridge, UK (2021)."},{"issue":"6","key":"e_1_3_6_36_2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials - Extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer NR","year":"2013","unstructured":"Latimer NR. Survival analysis for economic evaluations alongside clinical trials - Extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med. Decision Making 33(6), 743\u2013754 (2013).","journal-title":"Med. Decision Making"},{"issue":"4","key":"e_1_3_6_37_2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2522\/ptj.20130118","article-title":"Enhanced Therapeutic Alliance Modulates Pain Intensity and Muscle Pain Sensitivity in Patients With Chronic Low Back Pain: An Experimental Controlled Study","volume":"94","author":"Fuentes J","year":"2014","unstructured":"Fuentes J, Armijo-Olivo S, Funabashi M Enhanced Therapeutic Alliance Modulates Pain Intensity and Muscle Pain Sensitivity in Patients With Chronic Low Back Pain: An Experimental Controlled Study. Phys. Ther. 94(4), 477\u2013489 (2014).","journal-title":"Phys. Ther."},{"issue":"11","key":"e_1_3_6_38_2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1037\/hea0000499","article-title":"Harnessing the Placebo Effect: Exploring the Influence of Physician Characteristics on Placebo Response","volume":"36","author":"Howe LC","year":"2017","unstructured":"Howe LC, Goyer JP, Crum AJ. Harnessing the Placebo Effect: Exploring the Influence of Physician Characteristics on Placebo Response. Health Psychol. 36(11), 1074\u20131082 (2017).","journal-title":"Health Psychol."},{"key":"e_1_3_6_39_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyg.2016.00874","article-title":"Manipulating the Placebo Response in Experimental Pain by Altering Doctor's Performance Style","volume":"7","author":"Czerniak E","year":"2016","unstructured":"Czerniak E, Biegon A, Ziv A Manipulating the Placebo Response in Experimental Pain by Altering Doctor's Performance Style. Front. Psychol. 7, 1\u201310 (2016).","journal-title":"Front. Psychol."},{"issue":"2","key":"e_1_3_6_40_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal","volume":"38","author":"Phillippo DM","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal. Med. Decision Making 38(2), 200\u2013211 (2018).","journal-title":"Med. Decision Making"},{"key":"e_1_3_6_41_2","first-page":"1","volume-title":"NICE DSU Technical Support Document 18: Methods for Population-Adjusted Indirect Comparisons in Submissions to NICE.","author":"Phillippo DM","year":"2016","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU Technical Support Document 18: Methods for Population-Adjusted Indirect Comparisons in Submissions to NICE. National Institute for Health and Care Excellence (NICE) 1\u201382 (2016)."},{"issue":"4","key":"e_1_3_6_42_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 2","volume":"14","author":"Hoaglin DC","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 2. Value Health 14(4), 429\u2013437 (2011).","journal-title":"Value Health"},{"issue":"4","key":"e_1_3_6_43_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1","volume":"14","author":"Jansen JP","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1. Value Health 14(4), 417\u2013428 (2011).","journal-title":"Value Health"},{"key":"e_1_3_6_44_2","doi-asserted-by":"crossref","DOI":"10.1201\/b13613","volume-title":"The BUGS Book: A Practical Introduction to Bayesian Analysis (1st Edition).","author":"Lunn D","year":"2012","unstructured":"Lunn D, Jackson C, Best N, Thomas A, Spiegelhalter D. The BUGS Book: A Practical Introduction to Bayesian Analysis (1st Edition). Chapman and Hall\/CRC FL, USA (2012)."},{"issue":"2","key":"e_1_3_6_45_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA's Statement on p-Values: Context, Process, and Purpose","volume":"70","author":"Wasserstein RL","year":"2016","unstructured":"Wasserstein RL, Lazar NA. The ASA's Statement on p-Values: Context, Process, and Purpose. Am. Stat. 70(2), 129\u2013133 (2016).","journal-title":"Am. Stat."},{"key":"e_1_3_6_46_2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/bmj.322.7280.226","article-title":"Sifting the evidence-what's wrong with significance tests?","volume":"322","author":"Sterne JA","year":"2001","unstructured":"Sterne JA, Smith GD. Sifting the evidence-what's wrong with significance tests? BMJ 322, 226\u2013231 (2001).","journal-title":"BMJ"},{"key":"e_1_3_6_47_2","unstructured":"R Core Team. \u2018R: a language and environment for statistical computing\u2019 (2022). https:\/\/www.r-project.org\/"},{"key":"e_1_3_6_48_2","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-21416-0","volume-title":"Meta-Analysis with R.","author":"Schwartzer G","year":"2015","unstructured":"Schwartzer G, Carpenter J R, R\u00fccker G. Meta-Analysis with R. https:\/\/doi.org\/10.1007\/978-3-319-21416-0 (2015)."},{"issue":"2","key":"e_1_3_6_49_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/bmjebm-2017-110887","article-title":"Network meta-analysis: the highest level of medical evidence?","volume":"23","author":"Faltinsen EG","year":"2018","unstructured":"Faltinsen EG, Storeb\u00f8 OJ, Jakobsen JC, Boesen K, Lange T, Gluud C. Network meta-analysis: the highest level of medical evidence? BMJ Evid. Based Med. 23(2), 56\u201359 (2018).","journal-title":"BMJ Evid. Based Med."},{"key":"e_1_3_6_50_2","first-page":"1542","volume-title":"Headache: The Journal of Head and Face Pain.","author":"Forbes RB","year":"2020","unstructured":"Forbes RB, McCarron M, Cardwell CR. Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta-analysis. In: Headache: The Journal of Head and Face Pain. Blackwell Publishing Inc, MA, USA, 1542\u20131557 (2020)."},{"issue":"3","key":"e_1_3_6_51_2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/head.14255","article-title":"Patient preference for early onset of efficacy of preventive migraine treatments","volume":"62","author":"Ailani J","year":"2022","unstructured":"Ailani J, Winner P, Hartry A Patient preference for early onset of efficacy of preventive migraine treatments. Headache 62(3), 374\u2013382 (2022).","journal-title":"Headache"},{"issue":"6","key":"e_1_3_6_52_2","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3390\/jcm11061656","article-title":"New Generation Gepants: Migraine Acute and Preventive Medications","volume":"11","author":"Moreno-Ajona D","year":"2022","unstructured":"Moreno-Ajona D, Villar-Mart\u00ednez MD, Goadsby PJ. New Generation Gepants: Migraine Acute and Preventive Medications. J. Clin. Med. 11(6), 1656 (2022).","journal-title":"J. Clin. Med."},{"issue":"9","key":"e_1_3_6_53_2","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","article-title":"Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program","volume":"50","author":"Blumenfeld A","year":"2010","unstructured":"Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program. Headache 50(9), 1406\u20131418 (2010).","journal-title":"Headache"},{"issue":"7","key":"e_1_3_6_54_2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora SK","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7), 793\u2013803 (2010).","journal-title":"Cephalalgia"},{"issue":"7","key":"e_1_3_6_55_2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener HC","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7), 804\u2013814 (2010).","journal-title":"Cephalalgia"},{"issue":"6","key":"e_1_3_6_56_2","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1526-4610.2011.01915.x","article-title":"Botulinum toxin for the treatment of chronic migraine: the placebo effect","volume":"51","author":"Solomon S","year":"2011","unstructured":"Solomon S. Botulinum toxin for the treatment of chronic migraine: the placebo effect. Headache 51(6), 980\u2013984 (2011).","journal-title":"Headache"},{"issue":"21","key":"e_1_3_6_57_2","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1001\/jamainternmed.2013.10391","article-title":"Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis","volume":"173","author":"Meissner K","year":"2013","unstructured":"Meissner K, F\u00e4ssler M, R\u00fccker G Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis. JAMA Intern. Med. 173(21), 1941\u20131951 (2013).","journal-title":"JAMA Intern. Med."},{"issue":"4","key":"e_1_3_6_58_2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/npp.2012.227","article-title":"Personality trait predictors of placebo analgesia and neurobiological correlates","volume":"38","author":"Peci\u00f1a M","year":"2013","unstructured":"Peci\u00f1a M, Azhar H, Love TM Personality trait predictors of placebo analgesia and neurobiological correlates. Neuropsychopharmacology 38(4), 639\u2013646 (2013).","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_6_59_2","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3389\/fpsyg.2016.01876","article-title":"Can psychological expectation models be adapted for placebo research?","volume":"7","author":"Rief W","year":"2016","unstructured":"Rief W, Petrie KJ. Can psychological expectation models be adapted for placebo research? Front. Psychol. 7, 1876 (2016).","journal-title":"Front. Psychol."},{"key":"e_1_3_6_60_2","first-page":"e254","volume-title":"British Journal of Anaesthesia.","author":"Vase L","year":"2019","unstructured":"Vase L, Wartolowska K. Pain, placebo, and test of treatment efficacy: a narrative review. In: British Journal of Anaesthesia. Elsevier Ltd, Amsterdam, The Netherlands, e254\u2013e262 (2019)."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T11:31:18Z","timestamp":1688124678000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.57264\/cer-2023-0021"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0021","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"article-number":"e230021"}}